🔗 Share this article

As the United States undertakes unprecedented changes to its vaccine guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations during the global health crisis and has focused upon possible deaths following Covid immunization in her recent time at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Schedule

Health officials had intended to reveal radical changes to the pediatric vaccine schedule in December, bringing the US with the Danish immunization schedule, according to reports – a major change that would put the US at odds with a large portion of the world with no evidence for public health gain. This reveal has been delayed until the next year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this calendar year.

A New Direction at the Agency

This interim role could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has frequently advocated for ending some childhood shot schedules in the US so as to align more similar to Denmark's approach, a society with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

In her initial statements, she has kept her attention on immunizations – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Background

The appointee has no apparent experience in medication creation, regulation or leadership, which has been standard for past leaders of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the requisite experience” for overseeing the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who led CBER have had.”

This division has an immense workload at the FDA, the former commissioner emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and more, and every single one must be looked after,” Dr. Woodcock explained. “The area you neglect, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major management component to the job, which manages over 5,000 staff members. “It’s a huge management job, if you execute it properly,” the former official added.

Official Statement and Controversial Initiatives

In response to inquiries about Høeg’s qualifications and whether this selection signifies increased cooperation among agency officials on immunizations, a representative responded that the “concerns rely on inaccurate premises”.

“This background is consistent with the responsibilities of her role,” the official said, noting the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed expedited medication authorization process that allegedly concerned her former heads. “How are these medications being selected for this fast-track system? Who is making the decisions?” Howard said. “There’s a lot of secrecy happening at the agency right now.”

Broadly speaking, he said, “the agency appears to be shifting towards more relaxed oversight of pharmaceuticals, except for immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, history, critics said. She authored a study using non-validated public submissions to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current administration included altering guidelines for new vaccines and ending “optional” immunizations, she remarked following the vote on a online show. At the agency, Høeg has allegedly floated the idea of barring teenage boys from obtaining Covid vaccines.

“She’s an complete true believer who begins with her conclusions and works backwards to fit the evidence in a very deceptive, dishonest manner,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|